Last reviewed · How we verify
CLDM 1% gel
CLDM 1% gel is a Lincosamide antibiotic Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Acne vulgaris, Bacterial skin infections.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
GI148512, also known as CLDM 1% gel, is a treatment for Acne Vulgaris. It is a gel formulation that has been studied in clinical trials, including a study comparing it to a vehicle gel and a fixed dose combination gel, Duac.
At a glance
| Generic name | CLDM 1% gel |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Lincosamide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin works by binding to the bacterial 50S ribosomal subunit and inhibiting peptide bond formation, thereby preventing bacterial protein synthesis. This bacteriostatic action is effective against a broad range of gram-positive and anaerobic bacteria. The 1% gel formulation is designed for topical application to treat acne and other skin infections.
Approved indications
- Acne vulgaris
- Bacterial skin infections
Common side effects
- Dryness
- Erythema
- Peeling
- Oiliness
Key clinical trials
- DUAC® Early Onset Efficacy Study in Japanese Subjects (PHASE4)
- Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects (PHASE3)
- Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CLDM 1% gel CI brief — competitive landscape report
- CLDM 1% gel updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about CLDM 1% gel
What is CLDM 1% gel?
How does CLDM 1% gel work?
What is CLDM 1% gel used for?
Who makes CLDM 1% gel?
What drug class is CLDM 1% gel in?
What development phase is CLDM 1% gel in?
What are the side effects of CLDM 1% gel?
What does CLDM 1% gel target?
Related
- Drug class: All Lincosamide antibiotic drugs
- Target: All drugs targeting Bacterial 50S ribosomal subunit
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Acne vulgaris
- Indication: Drugs for Bacterial skin infections
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing